Table 5.
Prior studies of mRCC patients receiving HDIL-2 and associated response rates
| Study | Patient inclusion period | No. of patients (n) | CR (%) | PR (%) | SD (%) | PD (%) |
|---|---|---|---|---|---|---|
| Klapper et al. [27] | 1986–2006 | 259 | 23 (9) | 30 (12) | x | x |
| Belldegrun et al. [17] | 1989–2005 | 212 | 16 (8) | 25 (12) | 51 (29) | 110 (52) |
| Yang et al. [28] | 1991–2001 | 155 | 11 (7) | 22 (14) | x | x |
| McDermott et al. [29] | 1997–2000 | 95 | 8 (8.4) | 14 (14.7) | x | x |
| Morse et al. [18] | 2007–2012 | 97 | 7 (7.5) | 13 (14) | 22 (24) | 51 (55) |
| Payne et al. [30] | 1997–2012 | 186 | 12 (7) | 32 (17) | 54 (29) | 88 (47) |
mRCC metastatic renal cell carcinoma, HD high dose, IL-2 interleukin-2, CR complete response, PR partial response, SD stable disease, and PD progressive disease